Tvardi Therapeutics (TVRD) Times Interest Earned (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Times Interest Earned of -$9.43 for Q1 2026, up 93.79% sequentially from -$151.74 in Q4 2025, and down 1090.76% YoY from $0.95 in Q1 2025.
Tvardi Therapeutics (TVRD) Times Interest Earned (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Times Interest Earned for 14 years, with the latest figure at -$9.43 in Q1 2026.
- Quarterly Times Interest Earned fell 1090.76% year-over-year to -$9.43 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$39.36 (down 1363.56% YoY) and the FY2025 annual result came in at -$24.63, down 12917.44% from the prior year.
- Times Interest Earned improved to -$9.43 in Q1 2026 per TVRD's latest filing, from -$151.74 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.17 in Q3 2025 and troughed at -$220.45 in Q4 2024.
- A 5-year average of -$42.19 and a median of -$18.46 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2025: Times Interest Earned slumped 4240.46% in 2023, then soared 99.12% in 2025.
- Over 5 years, Times Interest Earned stood at -$63.37 in 2022, then decreased by 2.29% to -$64.83 in 2023, then sank by 240.07% to -$220.45 in 2024, then surged by 31.17% to -$151.74 in 2025, then soared by 93.79% to -$9.43 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$9.43, -$151.74, and -$0.17 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.43 |
| Dec 31, 2025 | -151.74 |
| Sep 30, 2025 | -0.17 |
| Jun 30, 2025 | -0.52 |
| Mar 31, 2025 | -0.79 |
| Dec 31, 2024 | -220.45 |
| Sep 30, 2024 | -1.30 |
| Jun 30, 2024 | -59.35 |
| Mar 31, 2024 | -21.77 |
| Dec 31, 2023 | -64.83 |
| Sep 30, 2023 | -20.67 |
| Jun 30, 2023 | -65.20 |
| Mar 31, 2023 | -18.46 |
| Dec 31, 2022 | -63.37 |
| Sep 30, 2022 | -9.59 |
| Jun 30, 2022 | -1.50 |
| Mar 31, 2022 | -8.06 |
| Dec 31, 2021 | -69.12 |
| Sep 30, 2021 | -2.33 |
| Jun 30, 2021 | -6.28 |